ライフサイエンスコーパス: DNA topoisomerase II

1 specifying functional doxorubicin-resistant DNA topoisomerase II.

2 for their inhibitory activity against human DNA topoisomerase II.

3 nd compound 11 was an in vitro, inhibitor of DNA topoisomerase II.

4 nism of substrate recognition and binding by DNA topoisomerase II.

5 ATP-modulated formation of contacts in yeast DNA topoisomerase II.

6 topopyrones A-D also act as poisons of human DNA topoisomerase II.

7 een the NH2- and COOH-terminal half of yeast DNA topoisomerase II.

8 ia secondary to therapy with drugs targeting DNA topoisomerase II.

9 sion of DNA topoisomerase IIbeta, one of two DNA topoisomerase II activities known to exist in mammal

10 The only DNA topoisomerase II activity conclusively demonstrated

11 Despite the likely requirement for a DNA topoisomerase II activity during synthesis of mitoch

12 ent study, we report the discovery of a type DNA topoisomerase II activity in bovine mitochondria.

13 The effect of these substitutions on DNA topoisomerase II activity is not known.

14 Alternatives include inhibition of DNA topoisomerase II activity, regulation of cell cycle

15 anticancer drugs are known to interfere with DNA topoisomerase II activity.

16 ealed that the 3F3/2 antibody binds to human DNA topoisomerase II alpha (HsTIIalpha) from mitotic but

17 from LLC-Pk was created in which endogenous DNA topoisomerase II alpha (topoII alpha) protein was do

18 we have characterized the recombinant human DNA topoisomerase II alpha containing either single or d

19 DNA topoisomerase II-an essential nuclear enzyme in DNA

20 an emerging ATPase superfamily that includes DNA topoisomerase II and Hsp90.

21 Footprinting of yeast DNA topoisomerase II and its NH2- and COOH-terminal trun

22 ized and evaluated for their effects against DNA topoisomerase II and KB or 1-resistant KB-7d tumor c

23 n synthesized and evaluated as inhibitors of DNA topoisomerase II and tumor cell growth in tissue cul

24 rren protein may function as an activator of DNA topoisomerase II and/or as a component of the Xenopu

25 have been screened for their potency against DNA topoisomerase II, and it has been observed that both

26 The enzyme DNA topoisomerase II associates with gene promoter regio

27 Human DNA topoisomerase II binding protein 1 (TopBP1) contains

28 The human DNA topoisomerase II-binding protein 1 (TopBP1) protein

29 by which merbarone, a catalytic inhibitor of DNA topoisomerase II, can block tumor cell growth withou

30 DNA topoisomerase II catalyzes two different chemical re

31 Induction of DNA topoisomerase II cleavage complexes in CEM and K562

32 oside and both etoposide metabolites induced DNA topoisomerase II cleavage complexes in the hematopoi

33 ransfer; however, consistent with reciprocal DNA topoisomerase II cleavage events in MLL and AF-4 in

34 etoposide, but also its metabolites, enhance DNA topoisomerase II cleavage near MLL translocation bre

35 The MLL genomic breakpoint was a functional DNA topoisomerase II cleavage site in an in vitro assay.

36 anslocation breakpoints in MLL and AF-4 were DNA topoisomerase II cleavage sites.

37 toposide metabolite- and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal hom

38 ibitor-related leukemias is a consequence of DNA topoisomerase II cleavage.

39 DNA topoisomerase II completely removes DNA intertwining

40 However, doxorubicin also binds to DNA topoisomerase II, converting the enzyme into a DNA d

41 The DNA topoisomerase II copurifies with mitochondria and di

42 mal breakage resulting from stabilization of DNA topoisomerase II covalent complexes by epipodophyllo

43 Repair of etoposide-stabilized DNA topoisomerase II covalent complexes may initiate MLL

44 amage the MLL breakpoint cluster region in a DNA topoisomerase II-dependent manner like the parent dr

45 F-beta activated kinase (TAK)1, TAB1, c-FOS, DNA topoisomerase II, DNA polymerase alpha, dihydrofolat

46 e phosphosites evolved from acidic residues (DNA topoisomerase II, enolase, and C-Raf) show that the

47 ontaining 100 mM NaCl, in which intact yeast DNA topoisomerase II exhibits robust DNA-dependent ATPas

48 ating that purified Saccharomyces cerevisiae DNA topoisomerase II exists as a stable dimer in solutio

49 In the preceding paper, we showed that DNA topoisomerase II from Saccharomyces cerevisiae binds

50 When bound to DNA, topoisomerase II from Saccharomyces cerevisiae exhi

51 de links across one dimer interface of yeast DNA topoisomerase II have confirmed this mechanism.

52 (eg, O6-methylguanine-DNA methyltransferase, DNA topoisomerase II, hMLH1, p21WAF1/CIP1; 4) activation

53 TA-3' sequences were reciprocally cleaved by DNA topoisomerase II in the presence of etoposide, etopo

54 does not serve as an essential activator of DNA topoisomerase II in vivo.

55 processing of the staggered nicks induced by DNA topoisomerase II, including exonucleolytic deletion

56 derivatives (11-23) were designed to enhance DNA topoisomerase II inhibition, overcome drug resistanc

57 F/SF and then exposed to Adriamycin (ADR), a DNA topoisomerase II inhibitor, exhibit an altered patte

58 DNA lesions generated by etoposide, a DNA topoisomerase II inhibitor, or by exonuclease treatm

59 Few t(9;11) translocations in DNA topoisomerase II inhibitor-related leukemias have be

60 al breakage leading to MLL translocations in DNA topoisomerase II inhibitor-related leukemias is a co

61 gesting that the bisdioxopiperazine class of DNA topoisomerase II inhibitors directly interacts with

62 24, and 25 were "cleavable-complex"-forming DNA topoisomerase II inhibitors with either improved or

63 Prior therapy in this patient included DNA topoisomerase II inhibitors, alkylating agents, and

64 s, were treated with various combinations of DNA topoisomerase II inhibitors, alkylating agents, or i

65 d alkylating agents, DNA topoisomerase I and DNA topoisomerase II inhibitors, and local radiation.

66 synthesis and biological evaluation of novel DNA topoisomerase II inhibitors, podophenazine (8), 2'',

67 Prior therapy included the DNA topoisomerase II inhibitors, teniposide and doxorubi

68 icancer treatment at low cumulative doses of DNA topoisomerase II inhibitors.

69 omplication of primary cancer treatment with DNA topoisomerase II inhibitors.

70 id leukemia who previously were treated with DNA topoisomerase II inhibitors.

71 igation of exposure to natural and synthetic DNA topoisomerase II inhibitors.

72 DNA topoisomerase II is a homodimeric molecular machine

73 DNA topoisomerase II is a molecular machine that couples

74 DNA topoisomerase II is the target of a variety of impor

75 DNA topoisomerase II modulates DNA topology by relieving

76 ty-two IIV-3 genes, including those encoding DNA topoisomerase II, NAD-dependent DNA ligase, SF1 heli

77 The DNA topoisomerase II poison and DNA damaging agent, etop

78 y a molar excess of Saccharomyces cerevisiae DNA topoisomerase II produces more negative-noded than p

79 n these results in the context of the entire DNA topoisomerase II reaction cycle are discussed.

80 omosomal recombination by simple exchange of DNA topoisomerase II subunits and DNA-strand transfer; h

81 t with a model in which binding of an intact DNA topoisomerase II to DNA places the various subfragme

82 enite-induced apoptosis was shown to involve DNA topoisomerase II (Top II) as selenite-induced apopto

83 sformed cells involves thiol modification of DNA topoisomerase II (Top2) based on the following obser

84 The breakage/reunion reaction of DNA topoisomerase II (TOP2) can be interrupted by DNA in

85 DNA topoisomerase II (TOP2) cleavable complexes represen

86 DNA topoisomerase II (Top2) is an essential nuclear enzy

87 DNA topoisomerase II (Top2) is the target of some of the

88 DNA topoisomerase II (TOP2) plays a pivotal role in fait

89 formed during replication are decatenated by DNA topoisomerase II (TOP2), and this process is activel

90 Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16)

91 ts is reversible and shown to be mediated by DNA topoisomerase II (TOP2).

92 ential targets have been proposed, including DNA topoisomerases II (Top2).

93 atch repair pathway, whereas another for the DNA topoisomerase II (TOP2A) poison etoposide identified

94 , 9, 12, and 13) were shown to inhibit human DNA topoisomerase II (topo II) activity at 5 microM.

95 DNA topoisomerase II (topo II) is a target for many clin

96 DNA topoisomerase II (topo II) is an essential nuclear e

97 ment with drugs that inhibit the function of DNA topoisomerase II (topo II) is being recognized with

98 py ALL (t-ALL) resulting from treatment with DNA topoisomerase II (topo II) targeting drugs.

99 drug that inhibits the catalytic activity of DNA topoisomerase II (topo II) without damaging DNA or s

100 ry, and one of the clones identified encoded DNA topoisomerase II (Topo II), an enzyme known to have

101 ffects in part via a catalytic inhibition of DNA topoisomerase II (topo II)alpha.

102 se ligands (2-5) were shown to inhibit human DNA topoisomerase-II (TOPO-II) activity at 10 microM.

103 DNA topoisomerase II uses a complex, sequential mechanis

104 A covalently cross-linked dimer of yeast DNA topoisomerase II was created by fusing the enzyme wi

105 lypeptide, the resulting heterodimeric yeast DNA topoisomerase II was found to nick plasmid DNA.

106 sis by two NH(2)-terminal fragments of yeast DNA topoisomerase II was studied in the absence and pres

107 Assuming that DNA topoisomerase II was the mediator of the breakage, p

108 Cysteine-substitution mutants of yeast DNA topoisomerase II were used to test footprinting of t

109 residues within the C-terminal half of yeast DNA topoisomerase II, which corresponds to the A subunit

110 Studies of yeast DNA topoisomerase II with various alanine-substitution m